Alnylam Pharma (ALNY) Tops Q4 EPS by 64c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $293.52 --0%
EPS Growth %: +409.4%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: +409.4%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of $0.06, $0.64 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $593.16 million versus the consensus estimate of $580.61 million.
GUIDANCE:
Alnylam Pharma sees FY2025 revenue of $2.05-2.25 billion, versus the consensus of $2.68 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
- Trident Digital Tech outlines AI expansion across its infrastructure
- Canaccord Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
